See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Donald Trump
Artificial Intelligence
Social Media
Tariffs
Natural Disasters
Vladimir Putin
Education
Inflation
MLB
European Union
South America
Immigration
Published • loading... • Updated

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM)

SUFFOLK COUNTY, MASSACHUSETTS, JUL 14 – Sana Biotechnology’s hypo-immune edited donor islet cells show durable clinical benefit and safety, driving a 150% stock rally and raising prospects for a type 1 diabetes cure.

Summary by Benzinga
An update on Sana Biotechnology.

2 Articles

WBURWBUR
Center

New diabetes trial provides at least temporary cure for small group of severe Type 1 patients

The study included 12 patients who suffer from a subset of Type 1 diabetes known as hypoglycemic unawareness, characterized by unexpected and dangerous drops in blood sugar

·Boston, United States
Read Full Article
BenzingaBenzinga
Center

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM)

An update on Sana Biotechnology.

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Monday, July 14, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Boston, Massachusetts icon

Boston, Massachusetts

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.

News
For You
SearchBlindspotLocal